Antiarrhythmic Drug Therapy

ApprovedSmall molecule

OOttawa Heart Institute Research Corporation

Antiarrhythmic Drug Therapy is one of 91 small molecule programs targeting Arrhythmia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArrhythmiaActive, not recruiting

Paroxysmal Atrial FibrillationActive, not recruiting

Atrial FibrillationApproved

ArrhythmiaApproved

Active, not recruiting

Paroxysmal Atrial FibrillationApproved

Active, not recruiting

Atrial FibrillationApproved

Approved

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Antiarrhythmic Drug Therapy

OOttawa Heart Institute Research Corporation

Approved

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 10

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Study completion

NCT06669299

Clinical

Trials by Indication[1]

Paroxysmal atrial fibrillation1 trial

A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF)

Completed·IIRCCS San Raffaele·Phase 4·NCT00340314·198 enrolled

Catheter Ablation1 trial

Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention

Terminated·OOttawa Heart Institute Research Corporation·Phase 4·NCT02114528·40 enrolled

Atrial Fibrillation1 trial

Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drugs in Persistent Atrial Fibrillation

Completed·AAZ Sint-Jan AV·N/A·NCT03437356·210 enrolled

Arrhythmia1 trial

Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias

Unknown status·—·Phase 4·NCT02303639·120 enrolled

Unspecified2 trials

CAB Versus Medical Therapy in Patients With AF and HF With Different EF Categories

Unknown status·—··NCT05364866·200 enrolled

Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies

Not yet recruiting·IIRCCS Ospedale San Raffaele·N/A·NCT06669299·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Antiarrhythmic Drug Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiarrhythmic Drug Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiarrhythmic Drug Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottawa Heart Institute Research Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: OOttawa Heart Institute Research Corporation

Antiarrhythmic Drug Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Paroxysmal atrial fibrillation1 trial

Catheter Ablation1 trial

Atrial Fibrillation1 trial

Arrhythmia1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News